DK1011637T3 - Modulation af fyldning af lægemiddel i multivesikulære liposomer - Google Patents

Modulation af fyldning af lægemiddel i multivesikulære liposomer

Info

Publication number
DK1011637T3
DK1011637T3 DK98945975T DK98945975T DK1011637T3 DK 1011637 T3 DK1011637 T3 DK 1011637T3 DK 98945975 T DK98945975 T DK 98945975T DK 98945975 T DK98945975 T DK 98945975T DK 1011637 T3 DK1011637 T3 DK 1011637T3
Authority
DK
Denmark
Prior art keywords
liposomes
osmolarity
aqueous component
active agent
lipid
Prior art date
Application number
DK98945975T
Other languages
Danish (da)
English (en)
Inventor
Qiang Ye
Nandini Katre
Mantripragada Sankaram
Original Assignee
Skyepharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skyepharma Inc filed Critical Skyepharma Inc
Application granted granted Critical
Publication of DK1011637T3 publication Critical patent/DK1011637T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98945975T 1997-09-08 1998-09-08 Modulation af fyldning af lægemiddel i multivesikulære liposomer DK1011637T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/925,532 US6106858A (en) 1997-09-08 1997-09-08 Modulation of drug loading in multivescular liposomes
PCT/US1998/018739 WO1999012523A1 (en) 1997-09-08 1998-09-08 Modulation of drug loading in multivesicular liposomes

Publications (1)

Publication Number Publication Date
DK1011637T3 true DK1011637T3 (da) 2007-05-21

Family

ID=25451864

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98945975T DK1011637T3 (da) 1997-09-08 1998-09-08 Modulation af fyldning af lægemiddel i multivesikulære liposomer

Country Status (14)

Country Link
US (1) US6106858A (de)
EP (1) EP1011637B1 (de)
JP (3) JP3676976B2 (de)
AT (1) ATE356614T1 (de)
AU (1) AU741784B2 (de)
CA (1) CA2303432C (de)
DE (1) DE69837339T2 (de)
DK (1) DK1011637T3 (de)
ES (1) ES2283071T3 (de)
IL (1) IL134703A (de)
NO (1) NO20001179L (de)
NZ (1) NZ503309A (de)
PT (1) PT1011637E (de)
WO (1) WO1999012523A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858589B2 (en) * 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
ES2343767T3 (es) * 1997-09-18 2010-08-09 Pacira Pharmaceuticals, Inc. Composiciones anestesicas liposomicas de liberacion sostenida.
JP4575592B2 (ja) * 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド 多小胞リポソームの製造
JP4198318B2 (ja) 1998-08-19 2008-12-17 ヤーゴテック アクチェンゲゼルシャフト プロポフォールの注射可能水性分散物
US6740643B2 (en) * 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
CA2389613A1 (en) * 1999-11-19 2001-05-25 Zycos Inc. Continuous-flow method for preparing microparticles
DE10109897A1 (de) * 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
DE10154464B4 (de) * 2001-11-08 2005-10-20 Max Delbrueck Centrum Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol
US20050118249A1 (en) * 2001-11-13 2005-06-02 Murray Webb Lipid carrier compositions and methods for improved drug retention
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7179484B2 (en) * 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
US20050129753A1 (en) * 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
CA2582949A1 (en) 2004-10-06 2006-04-13 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
CN1315530C (zh) * 2005-07-04 2007-05-16 重庆大学 蛋白质类药物控制释放系统制备方法
US20070110674A1 (en) * 2005-07-29 2007-05-17 Yuhong Xu Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems
JP5324223B2 (ja) 2005-12-08 2013-10-23 トランセイブ， インク． 肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
US20100196455A1 (en) * 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
WO2008137917A1 (en) * 2007-05-07 2008-11-13 Transave, Inc. Method of treating bacterial infections with antibacterial formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
JP5371030B2 (ja) * 2008-05-23 2013-12-18 国立大学法人 筑波大学 ベシクルの製造方法、この製造方法によって得られるベシクルおよびベシクルを製造するためのｗ／ｏ／ｗエマルション
WO2011001780A1 (ja) * 2009-07-02 2011-01-06 コニカミノルタホールディングス株式会社 特定分散剤を含有する外水相を利用する二段階乳化法によるリポソームの製造方法、ならびに当該リポソームの製造方法を用いるリポソーム分散液またはその乾燥粉末の製造方法およびそれにより製造されるリポソーム分散液またはその乾燥粉末
WO2011062255A1 (ja) * 2009-11-20 2011-05-26 コニカミノルタホールディングス株式会社 混合有機溶媒を油相として用いる二段階乳化によるリポソームの製造方法
WO2011127456A2 (en) 2010-04-09 2011-10-13 Pacira Pharmaceuticals, Inc. Method for formulating large diameter synthetic membrane vesicles
EP2394640A1 (de) 2010-05-21 2011-12-14 MediGene AG Verbesserte liposomale Formulierungen von lipophilen Verbindungen
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
DE102010042615A1 (de) 2010-10-19 2012-04-19 Wacker Chemie Ag 1:1, 2:1- oder 3:1-Komplex bestehend aus einem Cyclodextrin oder Cyclodextrinderivat und einem halogeniertem Ether, seine Herstellung und seine Verwendung als Schlafmittel
CN103260702B (zh) 2010-10-28 2018-07-27 帕西拉制药有限公司 非甾体类抗炎药的缓释制剂
KR20140092226A (ko) * 2010-12-14 2014-07-23 테크니칼 유니버시티 오브 덴마크 나노입자 조성물에서 방사성 핵종의 포집
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
EP2694040A4 (de) * 2011-03-25 2014-09-03 Selecta Biosciences Inc Synthetische nanoträger mit osmotisch vermittelter freisetzung
GB201119032D0 (en) 2011-11-03 2011-12-14 Isis Innovation Multisomes: encapsulated droplet networks
RS58985B1 (sr) * 2012-03-15 2019-08-30 Acraf Katjonski polimeri na bazi glikogena
CN104427976B (zh) 2012-05-10 2018-04-24 佩因拉佛姆有限公司 疏水的活性成分的储库制剂及其制备方法
PL2852391T3 (pl) 2012-05-21 2022-04-11 Insmed Incorporated Układy do leczenia infekcji płuc
GB201219201D0 (en) 2012-10-25 2012-12-12 Isis Innovation Hydrogel network
GB201219196D0 (en) 2012-10-25 2012-12-12 Isis Innovation Droplet assembly method
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
KR102449271B1 (ko) 2012-12-07 2022-09-29 옥스포드 유니버시티 이노베이션 리미티드 3d 프린팅에 의한 비말 어셈블리
US20140271507A1 (en) * 2013-03-13 2014-09-18 Stemetrix, Inc. Skin Compositions and Uses
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
EP3186281B1 (de) 2014-08-28 2019-04-10 Halozyme, Inc. Kombinationstherapie mit einer hyaluronanabbauendem enzym und einem immun-checkpoint-hemmer
MX381655B (es) 2015-05-04 2025-03-13 Versantis AG Metodo para preparar vesiculas con gradiente de ph de transmembrana.
CN109983013A (zh) 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
KR102069680B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019213398A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
JP2019218392A (ja) * 2019-08-30 2019-12-26 ズリ・ホールディングス・リミテッドＺｕｌｉ Ｈｏｌｄｉｎｇｓ Ｌｔｄ リポソーム、およびリポソームを含む処方剤
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) * 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
GB2627096A (en) 2021-10-14 2024-08-14 Pacira Pharmaceuticals Inc Bupivacaine multivesicular liposome formulations and uses thereof
US12251468B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12246092B1 (en) 2024-05-20 2025-03-11 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35192A (en) * 1862-05-06 Improved nutmeg-grater
JPH0768117B2 (ja) * 1983-05-06 1995-07-26 ベスター・インコーポレイテツド 薬剤放出調整用小胞製剤
CA1270198A (en) * 1984-08-08 1990-06-12 Marcel B. Bally Encapsulation of antineoplastic agents in liposomes
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5244678A (en) * 1986-01-14 1993-09-14 Ire-Celltarg S.A. Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
CA1335348C (en) * 1988-03-04 1995-04-25 Yasuaki Ogawa Liposome composition
US5261903A (en) * 1988-04-11 1993-11-16 M.D. Inc. Composite anesthetic article and method of use
BE1001869A3 (fr) * 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
USRE35192E (en) 1990-11-13 1996-03-26 Phoenix Surgical Products, Inc. Post-surgical anesthesia at a continuous and progressively decreasing administration rate
IS1685B (is) * 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
CA2093381A1 (en) * 1992-04-07 1993-10-08 Hideyuki Sawahara Liposome formulation and process for production thereof
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
JP3002702B2 (ja) * 1993-11-16 2000-01-24 スカイファーム インコーポレーテッド 活性物質の制御放出を有する小胞
US5451408A (en) * 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6106858A (en) * 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes

Also Published As

Publication number Publication date
EP1011637B1 (de) 2007-03-14
NO20001179L (no) 2000-04-04
PT1011637E (pt) 2007-03-30
ES2283071T3 (es) 2007-10-16
US6106858A (en) 2000-08-22
AU741784B2 (en) 2001-12-06
DE69837339D1 (de) 2007-04-26
DE69837339T2 (de) 2007-11-29
CA2303432C (en) 2008-02-12
WO1999012523A1 (en) 1999-03-18
EP1011637A4 (de) 2003-04-02
JP2008044962A (ja) 2008-02-28
AU9310198A (en) 1999-03-29
NZ503309A (en) 2001-04-27
JP3676976B2 (ja) 2005-07-27
EP1011637A1 (de) 2000-06-28
JP2001515853A (ja) 2001-09-25
JP2005120095A (ja) 2005-05-12
IL134703A0 (en) 2001-04-30
ATE356614T1 (de) 2007-04-15
CA2303432A1 (en) 1999-03-18
NO20001179D0 (no) 2000-03-07
IL134703A (en) 2005-08-31

Similar Documents

Publication Publication Date Title
NO20001179L (no) Modulering av legemiddel-lading i multivesikulære liposomer
ATE422878T1 (de) Formulierungen, welche dicht und weniger dicht mit igf-i beladen sind, zur verwendung in multivesikulären liposomen
DE69802688D1 (de) Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationen
DE69614685D1 (de) Mittel zur verzögerten freisetzung von menschlichem wachstumshormon
ES2171471T3 (es) Sistema para la administracion oral de desferrioxamina.
CL2009001870A1 (es) Composicion farmaceutica que comprende: a) un agente activo de prostaglandina que es 13,14-dihidro-15-ceto-20-etil-pgf2alfa isopropil ester, b) un primer tensoactivo no ionico, c) un segundo tensoactivo no ionico, d) un vehiculo oftalmicamente aceptable, util en el tratamiento de la hipertension ocular (divisional de la solicitud 557-98).
WO2001058474A3 (en) Microencapsulation and sustained release of biologically active agent
WO2004047801A3 (en) Method of drug loading in liposomes by gradient
AR007715A1 (es) Formulacion acuosa estable de un peptido, un metodo para preparar la misma y su uso para tratamiento
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
AR015524A1 (es) FORMULACIoN ESTABLE DE SOLUCIoN DE OXIPLATINO, SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO, PROCESO PARA SU PREPARACIoN, PRODUCTO FARMACÉUTICO QUE LA CONTIENE Y UN MÉTODO PARA ESTABILIZAR UNA SOLUCIoN DE OXALIPLATINO.
AR024337A1 (es) Sistemas portadores acuosos para ingredientes lipofilos
ATE148630T1 (de) Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen
ATE82496T1 (de) Vesikelformulierungen zur kontrollierten abgabe der wirkstoffe.
AU5347596A (en) External preparations for treating dermatoses
EA200000154A1 (ru) Способ солюбилизации фармацевтически активных ингредиентов в воде и в водных носителях
AR014772A1 (es) Una formulacion acuosa que permite la estabilizacion de conjugados de peg-interferon alfa durante y despues de la liofilizacion, proceso para producir un polvo liofilizado, un polvo liofilizado, un proceso para producir una solucion de los conjudados peg-interferon-alfa y un articulo de manufactura
FI955524A0 (fi) Kiinteinä liuoksina olevia valmisteita
PT873134E (pt) Formulacao aquosa de libertacao prolongada compreendendo factor de libertacao da hormona do crescimento bovino
BR0015422A (pt) Formulações de droga de liberação prolongada
SE9902742D0 (sv) New pharmaceutical formultion
CO4750838A1 (es) Metodo para el tratamiento de reacciones inflamatorias adversas y la composicion antiinflamatoria administrada